The Bellvitge Biomedical Research Institute (IDIBELL) is a research center in biomedicine promoted by the Bellvitge University Hospital and the Viladecans Hospital, both from the Catalan Health Institute, the Catalan Institute of Oncology, University of Barcelona and L’Hospitalet de Llobregat city council. In 2017, the Center for Regenerative Medicine of Barcelona (CMR[B]), now part of IDIBELL, launched the Program for Advancing the Clinical Translation of Regenerative Medicine of Catalonia (P-CMR[C]) together with IDIBELL.

IDIBELL research is focused in cancer, neuroscience, translational medicine and regenerative medicine. Research, innovation and society are the axes on which researchers work every day with the goal of improving the quality of life of citizens.

IDIBELL is located in L’Hospitalet de Llobregat, south of Barcelona. It is a CERCA Centre from the Catalan Government and a member of the Campus of International Excellence of the University of Barcelona (HUBc). In 2009, it became one of the first five Spanish research centers accredited as a health research institute by the Instituto de Salud Carlos III. In 2015, the European Commission recognized IDIBELL with the 'HR Excellence in Research' award, which identifies IDIBELL as a provider and supporter of a stimulating research work environment.